# LINKER-MM4 (NCT05828511)

> A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05828511
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Multiple Myeloma
- Interventions: Linvoseltamab
- Enrollment: 149
- Primary outcome: Incidence of Dose-Limiting Toxicities (DLTs)
- Primary outcome: Incidence of Treatment-Emergent Adverse Events (TEAEs)
- Primary outcome: Severity of TEAEs
- Primary outcome: Incidence of Adverse Events of Special Interest (AESIs)
- Primary outcome: Severity of AESIs
- Primary outcome: Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
- Primary outcome: Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
- Primary outcome: Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
- Primary outcome: Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
- Primary outcome: Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II

## Commentary we found

- X threads: 16
- YouTube: 7
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=linker-mm4-nct05828511

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05828511", "email": "<work email>"}; the inbox owner confirms by the emailed link.